Hyperactivation of midbrain dopaminergic system in schizophrenia could be attributed to the down-regulation of dysbindin
Authors:
- Shinsuke MatsuzakiSMShinsuke Matsuzaki
- Ryota HashimotoRHRyota Hashimoto
- 1 June 2006
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 345 (2) , 904-909
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Genetic mechanisms of psychosis: In vivo and postmortem genomicsClinical Therapeutics, 2005
- Genomic approaches to schizophreniaClinical Therapeutics, 2005
- The Emerging Role of Glutamate in the Pathophysiology and Treatment of SchizophreniaAmerican Journal of Psychiatry, 2001
- The Neuropsychopharmacology of Phencyclidine From NMDA Receptor Hypofunction to the Dopamine Hypothesis of SchizophreniaNeuropsychopharmacology, 1999
- A potential vulnerability locus for schizophrenia on chromosome 6p24–22: evidence for genetic heterogeneityNature Genetics, 1995
- Evidence for a susceptibility locus for schizophrenia on chromosome 6pter–p22Nature Genetics, 1995
- Provocative tests with psychostimulant drugs in schizophreniaPsychopharmacology, 1987
- CNS stimulants as tools in the study of schizophreniaTrends in Neurosciences, 1984
- Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic DrugsScience, 1976
- Antipsychotic Drugs: Direct Correlation Between Clinical Potency and Presynaptic Action on Dopamine NeuronsScience, 1975